Research progress of fenofibrate in the mechanism of myocardial hypertrophy

Abstract

Abstract: As lipid-regulating drug, the mechanism of fenofibrate is not clear. A large number of basic studies have been confirmed that it can inhibit myocardial hypertrophy. The clinical treatment of myocardial hypertrophy has provided a broad field of vision and theoretical basis. The treatment of fenofibrate in myocardial hypertrophy through the possible mechanism was reviewed. Further understanding of the other pharmacological effects of fenofibrate except for regulating blood lipid is needed. Further signal pathway and broader prospects are expected.

Key words: fenofibrate, myocardial hypertrophy, peroxisome proliferator activated receptor α, mechanism

CLC Number:

R541

HUANG Jin-xian, ZHOU Si-gui. Research progress of fenofibrate in the mechanism of myocardial hypertrophy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(3): 356-360.

References

[1] Yang L, Cai X, Liu J, et al. CpG-ODN attenuates pathological cardiac hypertrophy and heart failure by activation of PI3Kα-Akt signaling[J]. Plos One, 2013, 8(4): e62373.
[2] Pitchai B, Ankur R, Nanjaian M. Pleiotropic actions of fenofibrate on the heart[J]. Pharmacol Res, 2011, 63(1): 8-12.
[3] Oka T, Lam VH, Zhang L, et al. Cardiac hypertrophy in the newborn delays the maturation of fatty acid β-oxidation and compromises postischemic functional recovery[J]. Am J Physiol Heart Cric Physiol, 2011, 302(9): H1784-1794.
[4] Karbowska J, Kochan Z, Smolenski RT. Peroxisome proliferator-activated receptor alpha is downregulated in the failing human heart[J]. Cell Mol Biol left, 2003, 8(1): 49-53.
[5] 颜芳, 蔡乐, 陶杰, 等. 心血管疾病经济负担的研究现状及问题[J]. 中国慢性疾病预防与控制, 2009, 17(5): 547-548.
[6] Li R, Zheng W, Pi R, et al. Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy[J]. Febs Lett, 2007, 581(17): 3311-3316.
[7] Le K, Li R, Xu S, et al. PPARαactivation inhibits endothelin-1-induced cardiomycyte hypertrohy by prewention of NFATc4 binding to GATA-4[J]. NIH Public Access, 2011, 518(1): 71-78.
[8] Zou J, Le K, Xu S, et al.Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-αpartly via preventing p65-NFκB binging to NFATc4[J]. Mol Cell Endocrinol, 2013, 370(1/2): 103-112.
[9] Purushothaman S. Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart[J]. Card Phamacol, 2011, 58(3): 254-262.
[10] Sahoko I, Koji O, Yoshiji Y, et al. Attenuation of cardiac dysfunction by a PPAR-αagonist is associated with down-regulation of redox-regulated transcription factors[J]. Mol Cell Endocrinol, 2006, 41(2): 318-329.
[11] 张峰, 曾秋棠, 李宾公, 等. 非诺贝特对糖尿病性心肌病大鼠心肌炎症和心室重构的影响[J]. 郑州大学学报, 2009, 44(1): 136-139.
[12] 叶平, 方红, 周薪, 等. 非诺贝特和吡格列酮对心肌细胞肿瘤坏死因子-α表达的影响及机制的初探[J]. 中国药学杂志, 2004, 39(4): 257-259.
[13] 李传保, 卜培莉, 张运, 等. 非诺贝特对自发性高血压大鼠心肌重构及NF-κB表达的影响[J]. 山东大学学报, 2007, 45(1): 47-50.
[14] Takehiro O, Takashi M, Satoshi S, et al. Myocardial fibrosis and diastolic dysfunction in dexycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor -kappa-b pathway[J]. Am College of Card, 2004, 43(8): 1481-1488.
[15] 吴强, 杨永, 李隆贵, 等. 非诺贝特和吡格列酮对血管紧张素Ⅱ介导的心肌细胞肥大和凋亡的干预作用[J]. 中华高血压杂志, 2007, 15(3): 233-237.
[16] Deepa S, De Silva, Wilson RM, et al. Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms[J]. Am J Physiol Heart Circ Physiol, 2009, 296(6): 1983-1993.
[171] 罗文艳. PPARα/γ双激动剂的筛选及PPARγ抗糖异生作用机制的探讨[D]. 中国人民解放军军事医学科学院: 军事医学科学院放射与医学辐射研究所, 2008.
[18] Huang Y, Zhang H, Shao Z, et al. Suppression of enddothelin-1-induced cardiac myocyte hypertrophy by PPAR agonist:role of diacylglycerol kinase zeta[J]. Card Res, 2011, 90(2): 267-275.
[19] Rose M, Balakumar P, Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats[J]. Pharmacology, 2007, 80(2/3): 177-184.
[20] 万新红, 罗玉梅, 姜德谦, 等. 菲诺贝特和吡格列酮干预对代谢综合征大鼠心肌重构的影响[J]. 中国现代医学杂志, 2013, 23(4): 14-18.
[21] Wang M, Wang J, Tan R, et al. Effect of berberine on PPARα/NO activation in high glucose-and insulin-induced cardiomyocyte hypertrophy[J]. Evid Based Compl Alter Med, 2013, 2013: 285-489.
[22] 张懿玮. 病理性心肌肥大向心衰转变旳相关分子机制研究[D]. 长沙: 中南大学, 2009.
[23] 罗佳妮, 周四桂, 陈少锐, 等. 短链酯酰辅酶A脱氢酶与心肌肥大关系的初步探索[J]. 中国药理学通报, 2013, 29(5): 637-642.
[24] 刘薇, 郑强荪, 郭万刚, 等. 非诺贝特通过FOXO1抑制心肌肥大[J]. 现代生物医学进展, 2012, 12(8): 1449-1451.
[25] Rasouli N, Kern PA, Elbein SC,et al. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts[J]. Pharmaco Geno, 2012, 22(7): 484-497.
[26] Miranda S, González-Rodríguez Á, García-Ramírez M, et al. Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions[J]. J Cell Physiol, 2012, 227(6): 2352-2372.
[27] Ding F, Yu L, Wang M, et al. O-GlcNAcylation involvement in high glucose-induced cardiac hypertrophy via ERK1/2 and cyclin D2[J]. Amino Acids, 2013, 45(2): 339-349.
[28] Valene C, Xiao R, Michel P, et al. Fenofibrate, a peroxisome proliferator-activated receptor α agonist, exerts neuroprotective effects in traumatic brain injury[J]. Neuro Letters, 2005, 388(1): 7-12.